Collecting practice-changing clinical trials in Internal Medicine + subspecialties to promote EBM knowledge among medical learners - https://t.co/7oxB3t6Geg
Oct 29, 2022 • 7 tweets • 5 min read
Landmark trial thread🧵
This series of tweets will be about key trials studying SGLT-2 inhibitors in heart failure. While initially studied for DM, these meds were shown to improve CV outcomes in CHF patients, regardless of DM status.
#MedEd#EBM#CardioTwitter#clinicaltrials1) DAPA-HF trial:
Among patients with a reduced EF, the risk of worsening heart failure or death from CV causes was lower among those who received dapagliflozin vs placebo.